March 29th 2023
Investigators are assessing tirabrutinib, which received orphan drug designation from the FDA, as a treatment for patients with relapsed or refractory primary central nervous system lymphoma in the phase 2 PROSPECT study.
March 20th 2023
FDA Decides Not to Approve 131I-Omburtamab for Neuroblastoma With CNS/Leptomeningeal MetastasesDecember 5th 2022
The FDA has followed the recommendation of its Oncologic Drugs Advisory Committee and issued a complete response letter denying approval to 131I-omburtamab as a treatment for central nervous system and leptomeningeal metastases stemming from neuroblastoma.
Dendritic Cell Vaccination Meaningfully Improves Survival Outcomes in Newly Diagnosed and Recurrent GlioblastomaNovember 21st 2022
Autologous tumor lysate–loaded dendritic cell vaccine plus standard-of-care therapy improved survival outcomes vs standard-of-care alone in newly diagnosed and recurrent glioblastoma.
Chemo Delivered Via Subcutaneous Catheter-Pump System May Safely and Effectively Treat GlioblastomaNovember 15th 2022
Pulsatile, convection-enhanced delivery of topotecan using a novel subcutaneous catheter-pump system implanted into the brain showed promising efficacy signals in patients with glioblastoma, according to findings from a phase 1b clinical trial.
FDA’s ODAC Casts 16 to 0 Vote Against Omburtamab in Pediatric Metastatic NeuroblastomaNovember 3rd 2022
Members of the FDA’s Oncologic Drugs Advisory Committee indicated there isn’t enough evidence to definitively confirm the overall survival benefit of 131I-omburtamab in pediatric patients with central nervous system or leptomeningeal metastases stemming from neuroblastoma.
ASTRO Releases Clinical Guidelines on the Treatment of IDH-Mutated Grade 2/3 Diffuse GliomaSeptember 8th 2022
Guidelines from the American Society for Radiation Oncology on the use of radiation therapy for patients with IDH-mutant glioma included strong recommendations for close surveillance in IDH-mutant, 1p/19q codeleted, WHO grade 2 oligodendroglioma with no high-risk features and adjuvant radiotherapy for those with WHO grade 3 disease.
Laser Interstitial Thermal Therapy Appears to be a Promising Option in New, Recurrent GlioblastomaAugust 23rd 2022
Results from a multicenter study showed similar median overall survival results with laser interstitial thermal therapy compared with other tumor resection studies that used radiation and chemotherapy followed by laser ablation in patients with IDH wild-type glioblastoma.
FDA Grants Orphan Drug, Fast Track Designation to CV-01 Delivery of Sonodynamic Therapy for Recurrent GlioblastomaJuly 15th 2022
CV-01 delivery of sonodynamic therapy has been granted orphan drug designation and fast track designation by the FDA for the treatment of recurrent glioblastoma.
Investigators Provide Long-Term Follow-Up for 2 Phase 3 Trials of PCV Chemotherapy/RT for Anaplastic Oligodendroglial TumorsJune 30th 2022
According to long-term data, first-line treatment with procarbazine, lomustine, and vincristine chemotherapy plus radiotherapy offered prolonged disease control and survival benefit in anaplastic oligodendroglial tumors.
H3K27M+ Diffuse Intrinsic Pontine Gliomas Derive Benefit from GD2-Directed CAR T-cell TherapyApril 11th 2022
Children and young adults with H3K27M-positive diffuse intrinsic pontine gliomas and spinal diffuse midline gliomas saw a clinical benefit when treated with GD2-directed chimeric antigen receptor T cell therapy.
Recommended Dose of Ceritinib Yields Promising Early Activity in in ALK+ MalignanciesFebruary 21st 2022
The recommended dose of ceritinib once daily with food demonstrated promising preliminary clinical activity in patients with ALK-positive relapsed/recurrent inflammatory myofibroblastic tumors and anaplastic large cell lymphoma, and certain subsets of relapsed/refractory neuroblastoma.
Tumor Treating Fields Plus Pembrolizumab and Temozolomide Improve PFS in GlioblastomaNovember 17th 2021
Patients with newly diagnosed glioblastoma saw improved progression-free survival when treated with tumor treating fields, pembrolizumab, and temozolomide versus historical control data.
A Rare Case of Glioblastoma With Extensive Liver MetastasesNovember 15th 2021
Ghulam Gous, MD, and colleagues report a case of glioblastoma with extensive liver metastases along with a review of previous reports of liver metastasis from glioblastomas and the possible mechanisms of metastasis.
Carboplatin Therapy Intensification Results in Improved 5-Year EFS in Pediatric High-Risk Group 3 MedulloblastomaAugust 11th 2021
Pediatric patients with high-risk molecular subgroup group 3 medulloblastoma experienced an improvement in 5-year event-free survival after receiving therapy intensification with carboplatin.